the expression level of serum miR-214 and miR-143 in acute mveloid leukemia and their relationship with disease recurrence Luo Ting , Liu li, Rao 0i, Wu Han, Shen Kai. Department of Hematology, West China Hospital , Sichuan Unwersity/West China School of Nursing , Sichuan Unwersity , Sichuan Province, Chengdu 610044 , ChinaCorresponding author;Shen Kai, E-mail :545235787@ q9. comFunding program: Sichuan Natural Science Foundation Project ( 2022NSFSC1463)

Abstract：

Objective To investigate the expression level of serum microRNA(miR)-214 and miR-143 in patients with acute myeloid leukemia(AML), and analyze the relationship between them and relapse after AML treatment.Methods Ninety-four AML patients treated in the Department of Hematology, West China Hospital, Sichuan University from January 2019 to April 2021 were selected as the study subjects(AML group). According to whether the AML patients recurred within 1 year after treatment, they were divided into 60 AML remission subgroups and 34 AML recurrence subgroups. In addition, 50 healthy people in the same hospital were selected as the healthy control group. The expression levels of serum miR-214 and miR-143 were detected by real-time fluorescence quantitative PCR; Spearman grade correlation analysis was used to analyze the relationship between the expression of serum miR-214 and miR-143 and the relapse of AML patients after treatment. Multivariate logistic regression analysis was used to analyze the influencing factors of relapse of AML patients. The work characteristic curve(ROC) analysis of subjects was used to analyze the level of serum miR-214 and miR-143 to predict the efficacy of relapse of AML patients after treatment.Results The expression level of serum miR-214 in AML group was higher than that in healthy control group, and the expression level of miR-143 was lower than that in healthy control group(t/P=7.024/<0.001, 7.191/<0.001). The serum miR-214 expression level of AML patients in the relapse subgroup was higher than that in the remission subgroup, and the miR-143 expression level was lower than that in the remission subgroup(t/P=2.940/0.004, 6.596/<0.001). The WBC of AML patients in the relapse subgroup was higher than that in the remission subgroup, and the levels of Hb and PLT were lower than those in the remission subgroup(t/P=3.788/<0.001, 2.093/0.039, 2.974/0.004). Recurrence of AML patients was positively correlated with the expression of serum miR-214(r/P=0.584/<0.001), and negatively correlated with the expression of serum miR-143(r/P=-0.428/<0.001). Multivariate logistic regression analysis showed that high WBC and miR-214 were risk factors for relapse in AML patients [OR(95% CI)=1.647(1.062-2.555), 1.392(1.031-1.879)], and high Hb, PLT and miR-143 were protective factors [OR(95% CI)=0.839(0.805-0.991), 0.714(0.514-0.992), 0.768(0.606-0.974)]. ROC curve analysis showed that the area under the curve of serum miR-214, miR-143 and their combination to predict the recurrence of AML was 0.765, 0.900 and 0.939. The combined prediction of the two was better than the single index prediction(Z/P=3.318/0.002, 2.342/0.019). Conclusion The expression of miR-214 and miR-143 in serum of AML patients were up-regulated and down-regulated, both of which were effective in predicting the recurrence of AML patients.

Acute myeloid leukemia;                    miR-214;                    miR-143;                    Recurrence;